相关实验视频
Updated: Jun 13, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.3K
采用模板聚合来降解致病性tau组件并改善运动功能
Lauren V C Miller1, Guido Papa2, Marina Vaysburd2
1UK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge CB2 0AH, UK; MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK.
Cell
|September 14, 2024
概括
一种新的"RING-Bait"策略针对神经退行性疾病中的有毒蛋白质聚合物. 这种方法可以选择性地降解病态的聚物,同时保留功能性蛋白质,从而提供一个有前途的治疗途径.
科学领域:
- 神经科学
- 分子生物学
- 生物化学
背景情况:
- 蛋白质聚合是神经退行性疾病的标志,构成重大治疗挑战.
- 目前的策略很难在不影响功能蛋白质的情况下选择性地去除聚合物.
研究的目的:
- 开发一种新的治疗策略",RING-bait",用于选择性降解蛋白质聚合物.
- 为了证明RING-Bait在向和去除病态tau聚合物的有效性.
主要方法:
- 设计了一种"RING-Bait"结构,将聚合蛋白序列与E3泛素连接酶结合起来.
- 在P301S tau转基因小鼠模型中使用腺相关病毒 (AAV) 进行脑透.
- 评估总体降解,病理减少和功能改善.
主要成果:
- 在RING-Bait专门降解的聚物中,保留了可溶性聚物.
- 这种策略对种子和细胞自主聚合有效,包括阿尔茨海默病和渐进性超核性脑提取物.
- 在P301S tau小鼠中,体内治疗减少了tau病理和改善了运动功能.
结论:
- 在神经退行性疾病中选择性清除蛋白质聚合物的新有效策略.
- 这种方法显示出治疗病的潜力,并且可以适应其他蛋白质病.
相关概念视频
Parkinson's Disease: Overview
498
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
498
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Assembly of Complex Microtubule Structures
1.8K
Complex microtubule structures are present in resting cells and in dividing cells. In resting cells, they are responsible for maintaining the cellular architecture, tracks for intracellular transport, positioning of organelles, assembly of cilia and flagella. They mediate the bipolar spindle assembly for chromosomal segregation and positioning of the cell division plate in dividing cells. The formation of microtubule complex structures depends on the cell type, cell stage, and cell function.
1.8K
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Microtubule Associated Proteins (MAPs)
4.2K
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
4.2K

